HOWL - NASDAQ

Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc.

HOWLยทNASDAQ

$1.04

-3.7%
HealthcareBiotechnology

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$50.48M
EPS-1.3200
P/E Ratio-0.48
Earnings Date05/07/2026
Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc. Fair Value Envelope

HOWL ยท NASDAQ

Our analysis suggests that HOWL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.04, this represents a potential HIDDEN relative to our calculated worth for Werewolf Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.04

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$292.4M
+ Cash & Equivalents$58.0M
Firm Value-$234.5M
- Debt$9.4M
Equity Value-$243.9M
/ Shares Outstanding45,725,397B
DCF Value-$5
OVERVALUED BY 613%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$56.2M
-$52.3M
-$48.8M
-$45.4M
-$42.3M
-$39.5M
-$36.8M
-$34.3M
-$31.9M
-$29.7M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$56.2M
-$52.3M
-$48.8M
-$45.4M
-$42.3M
-$39.5M
-$36.8M
-$34.3M
-$31.9M
-$29.7M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$52.0M
-$44.9M
-$38.7M
-$33.4M
-$28.8M
-$24.9M
-$21.5M
-$18.5M
-$16.0M
-$13.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your HOWL research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.